MedPath

Duration of luteal phase support with progesterone pessaries to improve the success rate in assisted reproduction cycles. A prospective randomised control trial. - DOLS

Phase 1
Conditions
Women undergoing assisted conception
Registration Number
EUCTR2006-000599-33-GB
Lead Sponsor
iverpool Women's NHS Foundation Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Not specified
Target Recruitment
460
Inclusion Criteria

Biochemical pregnancy 2 weeks after embryo transfer using a urinary pregnancy test.
Progesterone treatment (2 weeks) completed upto day of pregnancy test.
Fresh embryo IVF/ICSI cycle.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Frozen embryo transfer

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To determine if an extra 10 weeks of progesterone (to make 12 weeks), after embryo implantation, increases the successful clinical pregnancy rate in assisted conception;Secondary Objective: ;<br> Primary end point(s): Viable pregnancy at 14 weeks on ultrasound scan. (At end of period taking pessaries).<br> Live birth.<br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath